17 results about "Pigmented Epithelium" patented technology

To provide compositions containing RPE cells or RPE monolayers, as well as methods and materials for making RPE cells or RPE monolayers from, for example, stem cells (e.g., iPSCs).SOLUTION: Disclosed is a method for making a retinal pigment epithelium monolayer, the method comprising, or consisting essentially of, culturing stem cells in a container having a surface coated with fibrinogen, wherein the surface is coated with greater than 3 μg / mL of fibrinogen, wherein the cells are in contact with the fibrinogen, and wherein the cells form the retinal pigment epithelium monolayer.SELECTED DRAWING: None

Provided are a production method of retinal pigment epithelial (RPE) cells that improves differentiation induction efficiency of pluripotent stem cells into RPE cells, and can provide highly pure RPE cells by a simple and easy operation in a short period, a culture method of RPE cells that can stably grow and culture a cell, a toxicity / efficacy evaluation method using RPE cells useful for transplantation therapy, and a therapeutic drug for a retinal disease. The invention relates to a production method of RPE cells, comprising adhesion culture of human pluripotent stem cells using a culture substrate coated with a laminin-E8 fragment, a culture method of RPE cells, comprising adhesion culture of RPE cells using a culture substrate coated with a laminin-E8 fragment, a toxicity or efficacy evaluation method using RPE cells obtained by producing or culturing by the method, and a therapeutic drug for a retinal disease, containing the RPE cells.

The present invention addresses the problem of providing an inhibitor for retinochoroidal disorders, in particular, an inhibitor for retinochoroidal scar formation and retinochoroidal atrophy in an epiretinal, intraretinal or subretinal tissue. This problem can be solved by preparing an inhibitor for retinochoroidal disorders which comprises, as an active ingredient, (E)-4-(2-{3-[(1H-pyrazol-1-yl)methyl]-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl}vinyl)benzoic acid, an ester thereof or a salt of the same. The inhibitor for retinochoroidal disorders can inhibit collagen atrophy of retinal pigment epithelium cells, fibroblasts, glial cells and the like and thus inhibit retinochoroidal disorders.

The recombinant AAV capsid protein is characterized in that the recombinant AAV capsid protein is obtained by mutating a common region of natural AAV5 capsid proteins VP1, VP2 and VP3; or the natural AAV5 capsid protein is heterozygous with other AAV serotype capsids, and then a common region of VP1, VP2 and VP3 is mutated, wherein the mutation point corresponds to at least one mutation from the 310th site to the 736th site of the AAV5 capsid protein of SEQ ID NO: 1; the capsid protein is targeted to the retinal pigment epithelium through intravitreal delivery, the problems that in the prior art, delivery is difficult, and retinal pigment epithelium cells cannot be effectively transduced are solved, and the AAV capsid protein has high transduction rate and immune escape capacity.

The application discloses application of TAPI-1 in preparation of a drug for treating dry age-related macular degeneration, and belongs to the technical field of biological medicine. A dry age-related macular degeneration mouse model is constructed by using sodium iodate, and a TAPI-1 solution is injected into the vitreous body for treatment, and structural examination and histopathological examination are conducted on the mouse. The experimental results show that, compared with the control group, the retinal choroid structure of the mouse treated by TAPI-1 is more complete, the fundus lesion area is less, the damage degree of the pigment epithelium and the photoreceptor cell is lighter, and the expression level of the inflammatory molecules in the ocular tissue is lower, and the treatment effect is significant. The application firstly proposes that TAPI-1 is used for preparing a drug for treating and / or preventing dry age-related macular degeneration, a new treatment strategy is provided for the dry age-related macular degeneration, and the application has a wide application prospect.

Disclosed are methods for preparing retinal pigment epithelium (RPE) cells from pluripotent stem cells (PSCs). More particularly, it represents an automated method that combines in a sequential manner three differentiating agents to direct the differentiation of human PSCs into RPE cells.

This application relates to a method for inducing stem cells to differentiate into retinal pigment epithelial cells (RPE), comprising the following steps: culturing the pluripotent stem cells in a first culture medium before the pluripotent stem cells exhibit cell state decline after cell culture, wherein the first culture medium comprises DMEM medium, serum, β-mercaptoethanol, non-essential amino acids (NEAA), and L-glutamine. The method described in this application can significantly improve the efficiency of differentiation into RPE.

This invention discloses a method for inducing differentiation and preparing retinal pigment epithelial cells (iPSCs), comprising: treating iPSCs with a first-stage induction differentiation medium, changing the medium daily; discarding the medium, adding a second-stage induction differentiation medium, treating the cells again, changing the medium daily, and picking the cells into matrix gel-coated well plates; discarding the medium, adding a third-stage induction differentiation medium, allowing the cells to adhere, changing the medium again, and allowing the cells to proliferate and grow during this period, while removing contaminating cells. This invention achieves the directed differentiation of iPSCs into retinal pigment epithelial cells through different stages of induction; this method uses a novel culture medium formulation, providing a new approach and method for stem cell differentiation and directed culture.

High efficiency methods for producing retinal pigment epithelial cells from induced pluripotent stem cells (iPSCs) are disclosed herein. The iPSCs are produced from somatic cells, including retinal pigment epithelial (RPE) cells, such as fetal RPE stem cells. In some embodiments, the iPSC include a tyrosinase promoter operably linked to a marker. Methods are disclosed for using the RPE cells, such as for treatment. Methods for screening for agents that affect RPE differentiation are also disclosed.

The present invention relates to a pharmaceutical composition for use in the treatment of a disease involving undesired migration, proliferation and / or metaplasia of retinal pigment epithelium (RPE) cells in a subject wherein the pharmaceutical composition comprises at least one epidermal growth factor receptor (EGFR) antagonist.

The present invention relates to a method of differentiating an induced pluripotent stem cell into a retinal pigment epithelial cell. Additionally, the present invention relates to a retinal pigment epithelial cell culture obtainable by the differentiation method and a retinal pigment epithelial cell culture obtained by the differentiation method. In addition, the present invention concerns a retinal pigment epithelium consisting of or comprising a retinal pigment epithelial cell culture obtainable or obtained by the differentiation method. The present invention also relates to a pharmaceutical composition comprising a retinal pigment epithelial cell culture obtained by the differentiation method. The present invention concerns a method of treating a retinal degenerative disease in a subject, comprising administering to a subject a retinal pigment epithelial cell differentiated from the induced pluripotent stem cell by the method. Finally, the present invention also refers to an in vivo method of detecting the survival rate of a retinal pigment epithelial cell differentiated from an induced pluripotent stem cell by the defined method in a subject and an in vitro method of determining the immunogenicity of said retinal pigment epithelial cell differentiated from an induced pluripotent stem cell by the defined method in said subject, to whom said differentiated RPE cell has been pre-delivered.

Provided are a production method of retinal pigment epithelial (RPE) cells that improves differentiation induction efficiency of pluripotent stem cells into RPE cells, and can provide highly pure RPE cells by a simple and easy operation in a short period, a culture method of RPE cells that can stably grow and culture a cell, a toxicity / efficacy evaluation method using RPE cells useful for transplantation therapy, and a therapeutic drug for a retinal disease. The invention relates to a production method of RPE cells, comprising adhesion culture of human pluripotent stem cells using a culture substrate coated with a laminin-E8 fragment, a culture method of RPE cells, comprising adhesion culture of RPE cells using a culture substrate coated with a laminin-E8 fragment, a toxicity or efficacy evaluation method using RPE cells obtained by producing or culturing by the method, and a therapeutic drug for a retinal disease, containing the RPE cells.

To provide a method for producing retinal pigment epithelial cells.SOLUTION: A method of producing retinal pigment epithelium (RPE) cells, comprising the steps of: (a) culturing a cell population of undifferentiated human pluripotent stem cells on an adherent surface selected from the group consisting of laminin, fibronectin, vitronectin, collagen I and collagen IV in a medium comprising nicotinamide as a differentiation-inducing agent and lacking activin A under feeder cell-free conditions to obtain differentiated cells; (b) culturing the differentiated cells on the adherent surface in a medium comprising nicotinamide and one or more members of the TGF β superfamily selected from the group consisting of TGF β 1, TGF β 3, and activin A to obtain RPE cells, wherein at least 50% of the cells in the population of cells are Oct4 + TRA-1-60 +.SELECTED DRAWING: Figure 1

A method for treating and / or preventing diseases involving the retinal pigment epithelium, comprising administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, a racemic mixture thereof, the corresponding enantiomer, or, if applicable, the corresponding diastereomer, wherein: X is NH or O, R 11 R 12 and R 13 Independently selected groups consisting of hydrogen, fluorine, chlorine, trifluoromethyl, methyl, and difluoromethoxy groups; Group A consisting of residues of formulas (II)-(VII) or (VIII), where "*" indicates a point connected to the rest of the molecule; R2, R3, R4, R5, R2 I R3 I R4 I R5 I R2 II R3 II R4 II R5 II R2 III R3 III R4 III R5 III R2 IV R3 IV R4 IV R5 IV R2 V R3 V R4 V R5 V R2 VI R3 VI R4 VI and R5 VI R6 is independently selected from the group consisting of hydrogen, straight-chain or branched alkyl groups having 1 to 3 carbon atoms, fluorine, chlorine, bromine, methoxy, ethoxy, propoxy, trifluoromethyl, 2,2,2-trifluoroethyl and difluoromethoxy, and R6 is selected from the group consisting of hydrogen, straight-chain or branched alkyl groups having 1 to 3 carbon atoms, trifluoromethyl and 2,2,2-trifluoroethyl.

The application discloses application of a DKK1 inhibitor in preparation of a medicine for treating dry age-related macular degeneration. The application finds that DKK1 is obviously increased in expression in a sodium iodate (NaIO3)-induced dry AMD cell and animal model. In an in-vitro experiment, siRNA targeting DKK1 can protect the morphology of retinal pigment epithelial cells and reduce the mortality rate, and in an in-vivo experiment, shRNA targeting DKK1 can relieve patchy loss of retinal pigment epithelial cells and protect the retinal pigment epithelial cells. Therefore, the application provides a new treatment target and treatment strategy for dry AMD, and has important clinical application value.

The application discloses an SDOCT modal DR and RVO edema biomarker discovery method. The method first trains a deep learning model using collected SDOCT data to automatically classify SDOCT images of two different retinal diseases. Then, using feature visualization technology, the attention area of the deep model in the classification decision is displayed in the form of a heat map, and the distribution of the attention area of the deep model is counted, and accordingly, potential new biomarkers are proposed to distinguish the two diseases, and the new biomarkers include a group of quantitative features such as retinal outer layer (outer limiting membrane (ELM), elliptical zone (EZ) and retinal pigment epithelium (RPE)) fracture rate, blocking rate and average gray scale. Finally, statistical analysis is performed on these quantitative features, and features with strong statistical differences (p value less than 0.001) are used as the final newly discovered biomarkers.

The invention provides an application of a composite hydrogel loaded with C3G. Specifically, the invention provides an application of the C3G-loaded arabinoxylan / casein hydrogel in preparation of an ophthalmic preparation. The ophthalmic preparation is used for protecting blue light damage of eyes, especially blue light damage of retinal pigment epithelium cells (RPE cells). Experiments prove that the C3G-loaded composite hydrogel can maintain slow release for at least 12 hours, corresponds to an acute injury stage of blue light injury, and effectively improves RPE cell apoptosis and mitochondrial injury caused by blue light through oxidation resistance and inflammation inhibition.